April 25, 2013

Cancer Experts Against High Prices of Cancer Drugs

Cancer experts against the high prices of cancer drugs.
Over 100 experts in chronic myeloid leukemia (CML) write in the Blood Journal against the high prices of cancer drugs with specific focus on bosutinib, ponatinib and omacetaxine. 
The 3 new drugs, however, have been priced at astronomical levels: ponatinib at $138,000 per year, omacetaxine at $28,000 for induction and $14,000 per maintenance course, and bosutinib at about $118,000 per year
Of the 12 drugs approved by the FDA for various cancer indications in 2012, 11 were priced above $100,000 per year. Cancer drug prices have almost doubled from a decade ago, from an average of $5,000 per month to more than $10,000 per month
The expectations 
For CML, and for other cancers, we believe drug prices should reflect objective measures of benefit, but should also not exceed values that harm our patients and societies.
Earlier Hagop Kantarjian (of MD Anderson) and others had written about why are cancer drugs so expensive.

This discussion applies not just to cancer drugs but other super high priced drugs.

Tags: cancer drug prices, reduced prices for cancer drugs, generic cancer drug prices, how to reduce prices for high price drugs